Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 12/20 | 0.51 |
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503764 | 0.82 | NPC1 (0.40) | AURKARPS6KB1VNN1 | |
| SCHEMBL4494921 | 0.79 | AURKA (0.47) | CHEK1AURKARPS6KB1JAK3CD38 | |
| SCHEMBL14543450 | 0.78 | CHEK1 (0.45) | CHEK1KCNH2 | |
| SCHEMBL4500977 | 0.74 | JAK2 (0.54) | CHEK1JAK3KCNH2 | |
| SCHEMBL11888530 | 0.71 | AURKA (0.47) | CHEK1AURKARPS6KB1JAK3CD38 | |
| SCHEMBL13503459 | 0.69 | CSF1R (0.48) | CHEK1AURKARPS6KB1JAK3CD38 | |
| SCHEMBL24566411 | 0.69 | AURKA (0.55) | AURKARPS6KB1JAK3CD38VNN1 | |
| SCHEMBL3255746 | 0.69 | AURKA (0.55) | AURKARPS6KB1JAK3CD38VNN1 | |
| SCHEMBL5453158 | 0.67 | JAK2 (0.62) | CHEK1JAK3 | |
| SCHEMBL22261277 | 0.67 | JAK3 (0.59) | AURKARPS6KB1JAK3CD38VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CHEK1 3814/4885AURKA 4188/4885RPS6KB1 221/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CHEK1 3814/4885AURKA 4188/4885RPS6KB1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.